<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01676727</url>
  </required_header>
  <id_info>
    <org_study_id>Advance-DA</org_study_id>
    <nct_id>NCT01676727</nct_id>
  </id_info>
  <brief_title>ADVANCE Direct Aortic</brief_title>
  <acronym>ADVANCE DA</acronym>
  <official_title>CoreValve® ADVANCE Direct Aortic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <brief_summary>
    <textblock>
      This study is intended to collect data regarding the clinical utility, safety and performance
      of the Medtronic CoreValve® System for Transcatheter Aortic Valve Implantation (TAVI) in
      patients with severe symptomatic aortic valve stenosis for which treatment via direct aortic
      access (DA) is selected. As part of the study analysis, resource utilization together with
      the Quality of Life questionnaires data will provide an important input into cost
      effectiveness analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days post-implant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)-Combined safety endpoint</measure>
    <time_frame>1, 6 and 12 months</time_frame>
    <description>The combined safety endpoint is defined as a composite of:
All-cause mortality
All stroke
Life-threatening bleeding
Acute kidney injury—Stage 3 (including renal replacement therapy)
Coronary artery obstruction requiring intervention
Major vascular complication
Valve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)
High degree AV block requiring permanent pacemaker implantation</description>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Valvular Heart Disease</condition>
  <condition>Transcatheter Aortic Valve Implantation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe aortic stenosis who are scheduled for an elective transcatheter aortic
        valve implantation and who are selected (e.g. because of an calcified femoral artery) to
        receive the CoreValve® device via direct aortic access.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe symptomatic aortic valve stenosis requiring treatment

          2. Acceptable candidate for elective treatment with the Medtronic CoreValve® System
             according to the most recent version of the Medtronic CoreValve® Instructions For Use

          3. 21 years of age or older

          4. Patient is willing and able to comply with all protocol-specified follow-up
             evaluations

          5. The patient or legal representative has been informed of the nature of the study and
             has consented to participate, and has authorized the collection and release of his/her
             medical information by signing a consent form (&quot;Patient Informed Consent Form&quot;)

          6. Patient will receive the CoreValve® device via direct aortic approach TAVI -

        Exclusion Criteria:

          1. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine,
             clopidogrel, nitinol, or sensitivity to contrast media which cannot be adequately
             pre-medicated

          2. Sepsis, including active endocarditis

          3. Recent myocardial infarction (&lt;30 days)

          4. Left ventricular or atrial thrombus by echocardiography

          5. Uncontrolled atrial fibrillation

          6. Mitral or tricuspid valvular insufficiency (&gt;grade II)

          7. Previous aortic valve replacement (mechanical valve or stented bioprosthetic valve)

          8. Evolutive or recent (within 6 months of implant procedure) cerebrovascular accident
             (CVA) or transient ischemic attack (TIA)

          9. Patients with:

               1. Vascular conditions that make insertion and endovascular access to the aortic
                  valve impossible, or

               2. Symptomatic carotid or vertebral arterial narrowing (&gt;70%) disease, or

               3. Thoracic aortic aneurysm in the path of delivery system

         10. Bleeding diathesis or coagulopathy

         11. Patient refuses blood transfusion

         12. Estimated life expectancy of less than 12 months unless TAVI is performed

         13. Creatine clearance &lt;20 mL/min

         14. Active gastritis or peptic ulcer disease

         15. Pregnancy or intent to become pregnant during study follow up

         16. Patient is participating in another trial that may influence the results of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Moat, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Brompton Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Bruschi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda spedaliera Niguarda Ca' Granda Milano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemocnice Podlesi Trinec</name>
      <address>
        <city>Trinec</city>
        <zip>739 61</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059 CEDEX 9</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda spedaliera Spedali Civili Di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda spedaliera Niguarda Ca' Granda Milano</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals NHS Trust, Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Norway</country>
    <country>Poland</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2012</study_first_submitted>
  <study_first_submitted_qc>August 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2012</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter Aortic valve Implantation</keyword>
  <keyword>Heart Valve Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>September 6, 2016</submitted>
    <returned>October 26, 2016</returned>
    <submitted>October 27, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

